BMY
Price
$47.14
Change
-$0.00 (-0.00%)
Updated
Aug 26, 11:28 AM (EDT)
Capitalization
95.95B
65 days until earnings call
MRK
Price
$85.28
Change
-$0.02 (-0.02%)
Updated
Aug 26, 11:46 AM (EDT)
Capitalization
213.09B
65 days until earnings call
Interact to see
Advertisement

BMY vs MRK

Header iconBMY vs MRK Comparison
Open Charts BMY vs MRKBanner chart's image
Bristol-Myers Squibb
Price$47.14
Change-$0.00 (-0.00%)
Volume$3.69K
Capitalization95.95B
Merck & Co
Price$85.28
Change-$0.02 (-0.02%)
Volume$5.34K
Capitalization213.09B
BMY vs MRK Comparison Chart in %
Loading...
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BMY vs. MRK commentary
Aug 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and MRK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 26, 2025
Stock price -- (BMY: $47.14 vs. MRK: $85.31)
Brand notoriety: BMY and MRK are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BMY: 90% vs. MRK: 73%
Market capitalization -- BMY: $95.95B vs. MRK: $213.09B
BMY [@Pharmaceuticals: Major] is valued at $95.95B. MRK’s [@Pharmaceuticals: Major] market capitalization is $213.09B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $623.33B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMY’s FA Score shows that 2 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).

  • BMY’s FA Score: 2 green, 3 red.
  • MRK’s FA Score: 2 green, 3 red.
According to our system of comparison, BMY is a better buy in the long-term than MRK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMY’s TA Score shows that 8 TA indicator(s) are bullish while MRK’s TA Score has 6 bullish TA indicator(s).

  • BMY’s TA Score: 8 bullish, 2 bearish.
  • MRK’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, BMY is a better buy in the short-term than MRK.

Price Growth

BMY (@Pharmaceuticals: Major) experienced а -2.18% price change this week, while MRK (@Pharmaceuticals: Major) price change was +1.29% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.53%. For the same industry, the average monthly price growth was +2.25%, and the average quarterly price growth was +12.48%.

Reported Earning Dates

BMY is expected to report earnings on Oct 30, 2025.

MRK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-0.53% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRK($213B) has a higher market cap than BMY($96B). BMY has higher P/E ratio than MRK: BMY (18.93) vs MRK (13.14). MRK YTD gains are higher at: -12.637 vs. BMY (-13.698). MRK has higher annual earnings (EBITDA): 25B vs. BMY (15.1B). BMY has more cash in the bank: 13.6B vs. MRK (8.62B). MRK has less debt than BMY: MRK (35.4B) vs BMY (50.9B). MRK has higher revenues than BMY: MRK (63.6B) vs BMY (47.7B).
BMYMRKBMY / MRK
Capitalization96B213B45%
EBITDA15.1B25B60%
Gain YTD-13.698-12.637108%
P/E Ratio18.9313.14144%
Revenue47.7B63.6B75%
Total Cash13.6B8.62B158%
Total Debt50.9B35.4B144%
FUNDAMENTALS RATINGS
BMY vs MRK: Fundamental Ratings
BMY
MRK
OUTLOOK RATING
1..100
720
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
9
Undervalued
PROFIT vs RISK RATING
1..100
10071
SMR RATING
1..100
3326
PRICE GROWTH RATING
1..100
5955
P/E GROWTH RATING
1..100
4391
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (6) in the Pharmaceuticals Major industry is in the same range as MRK (9). This means that BMY’s stock grew similarly to MRK’s over the last 12 months.

MRK's Profit vs Risk Rating (71) in the Pharmaceuticals Major industry is in the same range as BMY (100). This means that MRK’s stock grew similarly to BMY’s over the last 12 months.

MRK's SMR Rating (26) in the Pharmaceuticals Major industry is in the same range as BMY (33). This means that MRK’s stock grew similarly to BMY’s over the last 12 months.

MRK's Price Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as BMY (59). This means that MRK’s stock grew similarly to BMY’s over the last 12 months.

BMY's P/E Growth Rating (43) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (91). This means that BMY’s stock grew somewhat faster than MRK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMYMRK
RSI
ODDS (%)
Bullish Trend 1 day ago
61%
Bearish Trend 1 day ago
57%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
50%
Bearish Trend 1 day ago
67%
Momentum
ODDS (%)
Bullish Trend 1 day ago
48%
Bullish Trend 1 day ago
46%
MACD
ODDS (%)
Bullish Trend 1 day ago
52%
Bullish Trend 1 day ago
45%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
53%
Bullish Trend 1 day ago
50%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
53%
Bullish Trend 1 day ago
46%
Advances
ODDS (%)
Bullish Trend 14 days ago
53%
Bullish Trend 5 days ago
47%
Declines
ODDS (%)
Bearish Trend 1 day ago
54%
Bearish Trend 27 days ago
51%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
52%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
43%
Bullish Trend 1 day ago
60%
View a ticker or compare two or three
Interact to see
Advertisement
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NANR60.820.15
+0.24%
SPDR S&P® North American Natural Res ETF
NRES25.75N/A
N/A
Xtrackers RREEF Global Natrl Res ETF
SHDG30.86-0.04
-0.12%
Soundwatch Hedged Equity ETF
SDVY37.85-0.30
-0.79%
First Trust SMID Cp Rising Div Achv ETF
KSEP26.60-0.25
-0.93%
Innovator U.S. Small Cp Pwr Buf ETF -Sep